Autolus Therapeutics Ltd - Asset Resilience Ratio
Autolus Therapeutics Ltd (AUTL) has an Asset Resilience Ratio of 18.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Autolus Therapeutics Ltd (AUTL) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Autolus Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AUTL total assets.
Liquid Assets Composition Over Time
This chart breaks down Autolus Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read AUTL total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $98.51 Million | 18.69% |
| Total Liquid Assets | $98.51 Million | 18.69% |
Asset Resilience Insights
- Good Liquidity Position: Autolus Therapeutics Ltd maintains a healthy 18.69% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Autolus Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Autolus Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Autolus Therapeutics Ltd (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.37% | $196.58 Million | $589.07 Million | -12.70pp |
| 2024-12-31 | 46.08% | $360.64 Million | $782.73 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $375.38 Million | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more